key: cord-0258609-gkg3b4lx authors: Wygrecka, Malgorzata; Birnhuber, Anna; Seeliger, Benjamin; Michalick, Laura; Pak, Oleg; Schultz, Astrid-Solveig; Schramm, Fabian; Zacharias, Martin; Gorkiewicz, Gregor; David, Sascha; Welte, Tobias; Schmidt, Julius J.; Weissmann, Norbert; Schermuly, Ralph T.; Barreto, Guillermo; Schaefer, Liliana; Markart, Philipp; Brack, Markus C.; Hippenstiel, Stefan; Kurth, Florian; Sander, Leif E.; Witzenrath, Martin; Kuebler, Wolfgang M.; Kwapiszewska, Grazyna; Preissner, Klaus T. title: Altered fibrin clot structure contributes to thrombosis risk in severe COVID-19 date: 2021-09-17 journal: bioRxiv DOI: 10.1101/2021.09.17.460777 sha: 805eb5b779cea3c6608364d488466451fa3cf34f doc_id: 258609 cord_uid: gkg3b4lx The high incidence of thrombotic events suggests a possible role of the contact system pathway in COVID-19 pathology. Here, we demonstrate altered levels of factor XII (FXII) and its activation products in two independent cohorts of critically ill COVID-19 patients in comparison to patients suffering from severe acute respiratory distress syndrome due to influenza virus (ARDS-influenza). Compatible with this data, we report rapid consumption of FXII in COVID-19, but not in ARDS-influenza, plasma. Interestingly, the kaolin clotting time was not prolonged in COVID-19 as compared to ARDS-influenza. Using confocal and electron microscopy, we show that increased FXII activation rate, in conjunction with elevated fibrinogen levels, triggers formation of fibrinolysis-resistant, compact clots with thin fibers and small pores in COVID-19. Accordingly, we observed clot lysis in 30% of COVID-19 patients and 84% of ARDS-influenza subjects. Analysis of lung tissue sections revealed wide-spread extra- and intra-vascular compact fibrin deposits in COVID-19. Together, our results indicate that elevated fibrinogen levels and increased FXII activation rate promote thrombosis and thrombolysis resistance via enhanced thrombus formation and stability in COVID-19. Fibrinogen and FXIIa regulate fibrin network density in COVID-19 158 To assess whether enhanced activation of FXII in critically ill COVID-19 patients 159 represents a characteristic feature of SARS-CoV-2 infection, we analyzed plasma 160 samples of patients suffering from acute respiratory distress syndrome (ARDS) due to 161 influenza virus infection. The decrease in FXII plasma levels in severe COVID-19 was 162 confirmed in the validation cohort of the patients. Furthermore, the levels of FXII in 163 COVID-19 were significantly lower than those in ARDS-influenza ( Figure 2A ). 164 Surprisingly yet, the lag phase in fibrin formation, triggered by the FXII activator kaolin, 165 was shorter in plasma of critically ill COVID-19 patients as compared to patients 166 suffering from ARDS-influenza ( Figure 2B ). The phenomenon, which might be Further analysis of kaolin-triggered plasma clotting time revealed an increase in the 174 time to reach the turbidity peak in both patient groups as compared to control, but no 175 difference between ARDS-influenza and severe COVID-19 ( Figure 2D ). The density of 176 the clot (indicated by the maximum turbidity measurement) was higher in both patient 177 groups as opposed to control. A direct comparison between clots of ARDS-influenza 178 and severe COVID-19 showed significantly higher maximal turbidity values in the latter As the architecture of fibrin clots may be influenced not only by fibrinogen (FNG) but 209 also FXIIa 33,34 , we next analyzed the impact of these two proteins on the clot structure 210 in a purified system. As depicted in figure 3A high concentrations of fibrinogen 211 increased peak turbidity values and this effect was potentiated by the addition of FXIIa. Accordingly, corn trypsin inhibitor (CTI), the inhibitor of FXIIa, reduced maximum 213 turbidity of the clot generated by mixing fibrinogen and FXIIa ( Figure 3B ). As sustained activation of FXII was described in COVID-19 35 , we next investigated the Together, these results suggest that high levels of fibrinogen along with markedly 231 increased rates of FXII activation in COVID-19 plasma create a specific pro-232 coagulatory microenvironment, which promotes the formation of particularly dense Elevated fibrin network density increases clot resistance to fibrinolysis 251 Fibrin network density was previously found to determine clot resistance to 252 fibrinolysis 37 . Accordingly, we next evaluated the lysis resistance of fibrin clots in 253 patient plasma, using an in vitro turbidimetric clot-lysis assay. Here, kaolin together 254 with tissue-plasminogen activator (t-PA) were added to plasma to initiate the intrinsic 255 pathway of coagulation, followed by fibrin-dependent plasmin generation via t-PA- 16, 17 . Altogether haemostatic alterations seen in COVID-19 subjects reflect widespread Severe acute respiratory syndrome-632 related coronavirus: The species and its viruses -a statement of the 633 Clinical features of patients infected with 2019 635 novel coronavirus in Wuhan A new coronavirus associated with human 637 respiratory disease in China The Emerging Threat of (Micro)Thrombosis 639 in COVID-19 and Its Therapeutic Implications Understanding the Pathophysiology 641 of COVID-19: Could the Contact System Be the Key? Front Endothelial cell infection and 644 endotheliitis in COVID-19 COVID-19): Pulmonary Fibrosis and Vascular 672 Changes including Microthrombosis Formation Pathological study of the 2019 novel coronavirus 674 disease (COVID-19) through postmortem core biopsies Incidence of venous 677 thromboembolism in hospitalized patients with COVID-19 Among Critically Ill Patients With Coronavirus Disease The plasma contact system, a 683 protease cascade at the nexus of inflammation, coagulation and immunity Extracellular RNA constitutes 686 a natural procoagulant cofactor in blood coagulation Monocytes, neutrophils, and platelets 689 cooperate to initiate and propagate venous thrombosis in mice in vivo Proinflammatory and Procoagulant Mediators In Vivo The factor XIIa blocking antibody 3F7: A 715 safe anticoagulant with anti-inflammatory activities Anti-FXa Activity with Intermediate 718 Dose Thromboprophylaxis in COVID-19 Factor XIIa regulates the 721 structure of the fibrin clot independently of thrombin generation through direct 722 interaction with fibrin Causal relationship 724 between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in 725 mice Defective NET clearance 727 contributes to sustained FXII activation in COVID-19-associated pulmonary 728 thrombo-inflammation Coagulation abnormalities and thrombosis in 730 patients with COVID-19 Confirmation of the high times are related to elevated plasma levels of TAT, F1+F2, D-dimer and 756 FVIII:C Coagulopathy in COVID-19 ADAMTS13 regulation of VWF 760 multimer distribution in severe COVID-19 Altered properties of the fibrin gel 762 structure in patients with IDDM Altered Fibrin Clot Structure/Function in 764 Patients with Cryptogenic Ischemic Stroke Fibrin clot properties are altered in 766 patients with chronic obstructive pulmonary disease: Beneficial effects of 767 simvastatin treatment Proneness to formation of tight and rigid 769 fibrin gel structures in men with myocardial infarction at a young age Altered fibrin clot structure/function in 772 patients with idiopathic venous thromboembolism and in their relatives Influence of fibrin network conformation and 775 fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches 776 by confocal microscopy Plasma tissue plasminogen activator 778 and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. 779 medRxiv COVID-19: The crucial role of blood coagulation and fibrinolysis Plasma mediators in patients with 783 severe COVID-19 cause lung endothelial barrier failure Activation of the 786 factor XII-driven contact system in Alzheimer's disease patient and mouse 787 model plasma Coagulation biomarkers are 789 independent predictors of increased oxygen requirements in COVID-19 Acknowledgement